LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 6, 2007, Pages 873-879

  Mosca, Marta ^a   Baldini, Chiara ^a   Bombardieri, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Anti dsDNA antibodies; Flares; LJP 394; Lupus nephritis; Systemic lupus erythematosus

Indexed keywords

ABETIMUS; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; DNA; OLIGONUCLEOTIDE;

ANTIBODY TITER; ANTIGEN BINDING; BINDING AFFINITY; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; KIDNEY FAILURE; LABORATORY TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; REPEATED DRUG DOSE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANIMAL; BLOOD; CHRONIC KIDNEY FAILURE; IMMUNOLOGY;

ANIMALS; AUTOANTIBODIES; CLINICAL TRIALS; DNA; HUMANS; KIDNEY FAILURE, CHRONIC; LUPUS ERYTHEMATOSUS, SYSTEMIC; OLIGONUCLEOTIDES; TREATMENT OUTCOME;

EID: 34247891786     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.6.873     Document Type: Review

References (36)

1. LIPSKY PE: Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. (2001) 2:764-766.
2. URAMOTO KM, MICHET CJ, THUMBOO J, SUNKU J, O'FALLON WM, GABRIEL SE: Trends in the incidence and mortality of systemic lupus erythematosus. Arthritis Rheum. (1999) 42:46-50.
3. CERVERA R, KHAMASTA MA, FONT J et al., EUROPEAN WORKING PARTY ON SYSTEMIC LUPUS ERYTHEMATOSUS: Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (2003) 82:299-308.
4. PONTICELLI C, MORONI G: Flares in lupus nephritis: incidence, impact on renal survival and management. Lupus (1998) 7:635-638.
5. MOSCA M, BENCIVELLI W, NERI R et al.: Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int. (2002) 61:1502-1509.
6. AUSTIN HA III, KLIPPEL JH, BALOW JE et al.: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. NEJM (1986) 314:614-619.
7. BOUMPAS DT, AUSTIN HA III, VAUGHN EM et al.: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet (1992) 340:741-745.
8. HOUSSIAU FA, VASCONCELOS C, D'CRUZ D et al.: Immunosuppressive therapy in lupus nephritis the euro-lupus nephritis trial, a randomised trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. (2002) 46:2121-2131.
9. MOK CC, YING KY, NG WL et al.: Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am. J. Med. (2006) 119:355.e25-355.e33.
10. ILLEI GG, AUSTIN HA III, CRANE M et al.: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann. Int. Med. (2001) 135:248-257.
11. ILLEI GG, TAKADA K, PARKIN D et al.: Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term follow-up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. (2002) 46:995-1002.
12. MOK CC, YING KY, TANG S et al.: Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum. (2004) 8:2559-2568.
13. BONGU A, CHANG E, RAMSEY-GOLDMAN R: Can morbidity and mortality of SLE be improved? Best Pract. Res. Clin. Rheumatol. (2002) 16:313-332.
14. KATSIFIS GE, TZIOUFAS AG: Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus (2004) 13:673-678.
15. SCHATTNER A, NAPARSTEK Y: The future of the treatment of systemic lupus erythematosus. Clin. Exp. Rheumatol. (2005) 23:254-260.
16. O'NEIL SG, SCHRIEBER L: Immunotherapy of systemic lupus erythematosus. Autoimmun. Rev. (2005) 4:395-402.
17. DOOLEY MA, GINZLER EM: Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents. Rheum. Dis. Clin. North Am. (2006) 32:91-102.
18. LOONEY RJ, ANOLIK J, SANZ I: New therapies for systemic lupus erythematosus: cellular targets. Rheum. Dis. Clin. North Am. (2006) 32:201-215
19. KOURBETI IS, BOUMPAS DT: Biological therapies of autoimmune diseases. Curr. Drug Targets Inflamm. Allergy (2005) 4:41-46.
20. KIROU KA, SALMON JE, CROW MK: Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system. Rheum. Dis. Clin. North Am. (2006) 32:103-119.
21. ANOLIK JH, ARINGER M: New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract. Res. Clin. Rheumatol. (2005) 19:859-878.
22. WALLACE DJ, TUMLIN JA: LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus. Lupus (2004) 13:323-327.
23. RIBOLDI P, GEROSA M, MORONI G et al.: Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity (2005) 38:39-45.
24. LINNIK MD, HU JZ, HEILBRUNN KR et al.: Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. (2005) 52:1129-1137.
25. FURIE RA, CASH JM, CRONIN ME et al.: Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol. (2001) 28:257-265.
26. CARDIEL MH: Abetimus sodium: a new therapy for delaying the time to, and reducing the incidence of, renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease. Expert Opin. Investig. Drugs (2005) 141:77-88.
27. HARTLEY SB, COOKE MP, FULCHER DA et al.: Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell (1993) 72:325-335.
28. MCNEELY PA, IVERSON GM, FURIE RA et al.: Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients. Lupus (2001) 10:526-532.
29. LINNIK M, STAINES NA, BERDEN J, ISENBERG DA: Workshop report on some new ideas about the treatment of systemic lupus erythematosus. Lupus (2002) 11:793-796.
30. WEISMAN MH, BLUESTEIN HG: A pilot study of ljp 394, a novel therapeutic agent for the treatment of systemic lupus erythematosus. Arthritis Rheum. (1995) 38(Suppl.): S302.
31. CASH J, CRONIN M, KATZ R et al.: A dose-ranging study of LJP 394, a novel therapeutic agent for the treatment of systemic lupus erythematosus. Scand. J. Rheumatol. (1996) 106(Suppl.): 9.
32. HEPBURN B, FURIE R, CASH J et al.: Reduction of anti-dsDNA antibodies using LJP 394 in patients with lupus. Arthritis Rheum. (1996) 39(Suppl.): S307.
33. ALARCON-SEGOVIA D, TUMLIN JA, FURIE RA et al.: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus. Arthritis Rheum. (2003) 48:442-454.
34. CARDIEL MH, TUMLIN JA, FURIE RA et al.: Clinical efficacy results from a RCT of LJP 394 in SLE patients with history of renal disease. Arthritis Rheum. (2003) 48(Suppl.):S582-S583.
35. STRAND V, ARANOW C, CARDIEL MH et al.: Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomised clinical trial comparing LJP 394 treatment with placebo. Lupus (2003) 12:677-686.
36. BOMBARDIERI S, CARDIEL MA, TUMLIN JA et al.: Summary of safety results from studies of LJP 394 in SLE patients. Ann. Rheum. Dis. (2004) 63(Suppl.1): 216.